Havana, Jul 2.- The Prime Minister of Cuba, Manuel Marrero Cruz, recognized the work and contributions to science of the Center for Genetic Engineering and Biotechnology (CIGB), on the occasion of celebrating the 37th anniversary of its creation.
Through his Twitter account, the head of government sent congratulations to the CIGB work group, founded on the initiative of the historic leader of the Cuban Revolution, Fidel Castro Ruz.
The CIGB has marked the scientific history of the island and the world with the development of various drugs and vaccines such as two of the five Cuban immunogens against COVID-19: Mambisa and Abdala.
Abdala, the first vaccine conceived in Latin America, demonstrated 92.28 percent efficacy in its phase III clinical trial and millions of doses have already been administered in the Caribbean nation and in others such as Venezuela, Nicaragua, the Sahrawi Arab Democratic Republic and Vietnam. . Data from the center itself indicate that some 40 million doses of the Abdala vaccine were delivered to the Cuban Health System for mass vaccination against the viral disease.
Mambisa, for its part, is placed among the immunogens designed globally to be administered nasally and thus attack the main entrance of the SARS-CoV-2 coronavirus.
The CIGB has also been in charge of leading Cuban scientific products, such as the hepatitis B vaccine, the epidermal growth factor, the Heberpenta vaccine and the preparation of streptokinase, obtained for the first time in the world.
In addition, the institution has one of the most internationally recognized medicines to its credit: Heberprot-P, a unique and exclusive drug, designed to treat diabetic foot ulcers and reduce the risk of amputation. (Taken from Radio Cadena Agramonte)
2023-07-02 12:04:57
#work #Center #Genetic #Engineering #recognized #Cuba #Tweet #Radio #Santa #Cruz #Radio #Santa #Cruz
